PacBio executives set for fireside chat at Jefferies health conference
PacBio (NASDAQ: PACB) announced that its management will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026, at 2:00 PM ET in New York. A live webcast and 30-day replay of the event will be available on the company's investor website. This participation aims to offer additional investor visibility, with past financial results showing improved gross profit and narrowed net loss.
PacBio to Participate in the Jefferies Global Healthcare Conference
PacBio announced its management will participate in a fireside chat at the Jefferies' Global Healthcare Conference on June 4, 2026, in New York. A live webcast and replay of the event will be available on the company's investors page. PacBio is a life science technology company specializing in advanced sequencing solutions.
Publication spotlight: How one HiFi sequencing assay can bring clarity to unexplained infertility
A new study by the HiFi Solves Sub-fertility Consortium explores how HiFi long-read whole genome sequencing can provide a more complete genetic picture for couples experiencing unexplained infertility or recurrent pregnancy loss. This approach aims to reduce the need for multiple fragmented tests, offering a single, comprehensive assay to identify genetic variations. The study found clinically relevant insights in 1 in 10 couples, demonstrating the potential of this technology to streamline diagnosis and guide future research in reproductive genetics.
PACB & Blank Bio Partner to Advance RNA Foundation Models in Oncology
Pacific Biosciences (PACB) has partnered with Blank Bio, an AI research company, to advance RNA foundation models for precision oncology, including a $7.2 million seed investment. Blank Bio will utilize PacBio’s HiFi long-read sequencing technology to generate RNA sequencing data from tumor samples, with the goal of improving biomarker discovery, diagnostics, and clinical trial design. This collaboration aims to strengthen PacBio's position in the oncology market and expand the application of its technology in AI-driven precision medicine.
Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology
Blank Bio has secured $7.2 million in seed financing and entered a strategic collaboration with Pacific Biosciences (PacBio) to develop RNA foundation models for precision oncology. The initiative aims to leverage high-resolution long-read RNA sequencing data from tumor samples to improve patient-level prediction, biomarker discovery, and clinical trial design. This funding will support continued model development and expanded partnerships with pharmaceutical and diagnostic companies.
AI lab Blank Bio raises $7.2M, teams with PacBio on tumor RNA
Blank Bio, an AI research lab, has secured $7.2 million in seed financing and entered a strategic collaboration with Pacific Biosciences (Nasdaq: PACB). This partnership aims to advance RNA foundation models for precision oncology by generating high-resolution long-read RNA sequencing data from tumor samples. The funding will support model development, collaborations with pharmaceutical and diagnostic companies, and the creation of new RNA-seq datasets to enhance biomarkers, clinical trial design, and diagnostics.
PacBio tumbles after narrowing full-year revenue guidance
This article mentions that PacBio's stock tumbled after the company narrowed its full-year revenue guidance. It indicates that further details would be available in the main content.
Sequencing constraints lifted as Pacific Biosciences of California enables combined genetic and methylation detection
Pacific Biosciences of California has announced a new technology that allows researchers to detect both genetic variation and native methylation in a single sequencing run using its HiFi sequencing platform. This advancement eliminates the need for additional preparation steps, aiming to streamline data collection and overcome traditional challenges in genomic analysis. The company believes this will accelerate genetic research and provide more comprehensive insights for various clinical and scientific applications.
Pacific Biosciences of California (PACB) Stock Moves -4.04%: What You Should Know
Pacific Biosciences of California (PACB) stock experienced a daily loss of 4.04%, underperforming the S&P 500's gain of 0.20% on the same day. Over the past month, the stock has dropped 18.06%, while the broader Medical sector has declined by 1.6% and the S&P 500 has risen by 3.63%. Investors are advised to monitor its upcoming earnings report for potential market reaction.
PacBio expects $165M-$175M 2026 revenue as SPRQ-Nx ships later this month
PacBio anticipates generating between $165 million and $175 million in revenue in 2026. This projection comes as the company prepares to ship its SPRQ-Nx product later this month, which is expected to contribute to future revenue growth.
Pacific Biosciences of California introduces HiFi Starter Kit to expand long-read sequencing access
Pacific Biosciences of California (PacBio) has launched its HiFi Starter Kit to make long-read sequencing more accessible to researchers. This kit aims to simplify the adoption of HiFi sequencing by providing guidance on workflow integration, experiment planning, and scaling automation. The company has also been working to improve sequencing accuracy and reduce costs, demonstrating its commitment to advancing genetic research.
Pacific Biosciences stock (US6932471010): Latest developments and market position
Pacific Biosciences (PACB) continues to advance its long-read DNA sequencing technology, demonstrating ongoing innovation in genomics research and precision medicine. The company reported $48.8 million in Q4 2025 revenue, driven by consumables and sales of its Revio sequencing system, and operates within a growing long-read sequencing market. US investors are watching PACB due to its Nasdaq listing, its role in next-generation sequencing, and exposure to the expanding US genomics market.
The power of one: How assay consolidation and menu expansion reshape sequencing economics
This article discusses how assay consolidation and menu expansion, particularly through PacBio's HiFi long-read sequencing and SPRQ-Nx chemistry, are reshaping the economics of genomic testing. It highlights the benefits of moving from fragmented workflows with multiple assays and platforms to a single, comprehensive approach that reduces complexity, cost, and turnaround time while enhancing data completeness and utility for labs. The article presents a unified model that supports diverse applications, improving platform utilization and creating a more predictable operational framework for clinical labs, core facilities, and service providers.
Pacific Biosciences (PACB) Reports Q1 EPS
Pacific Biosciences (NASDAQ:PACB) reported Q1 EPS of (12c), narrowly beating the consensus estimate of (13c), but revenue of $37.18M fell short of the $39.98M estimate. Despite record consumables revenue driven by increasing clinical adoption of HiFi, instrument revenue, particularly from Vega, was below expectations. The company plans a broader commercial rollout of its SPRQ-Nx beta program and forecasts FY26 revenue between $165M-$175M.
PACB SEC Filings - Pacific Biosc 10-K, 10-Q, 8-K Forms
This article provides details on recent SEC filings for Pacific Biosciences of California, Inc. (PACB), including reports on insider stock sales by Christian Henry and Mark Van Oene, a shelf registration for various securities, and the company's annual report showing a focus on long-read sequencing and substantial losses. It also covers executive role reassignments and mixed Q4 and full-year 2025 financial results.
Pacific Biosciences of California, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:PACB) 2026-05-11
Pacific Biosciences of California, Inc. (PACB) published its Q1 2026 earnings call presentation, reporting an EPS of -$0.12, which beat estimates by $0.01. The company's revenue for the quarter was $37.18M, missing expectations by $2.80M, despite a 0.07% year-over-year increase. This article provides access to the slide deck presented during the earnings call.
Long-read genome scan spots key variants in unexplained subfertility
PacBio announced major findings from the HiFi Solves Sub-fertility Consortium in Asia Pacific, utilizing HiFi long-read whole genome sequencing to investigate unexplained subfertility and recurrent pregnancy loss. The study, involving 84 individuals across Asia-Pacific institutions, identified clinically relevant genomic findings in approximately one in 10 couples and likely diagnostic variants in 4.8% of individuals. This new approach aims to provide a more comprehensive genetic evaluation and reduce fragmented testing in reproductive genetics.
Pacific Biosciences Of California (PACB) Q4 Loss Highlights Ongoing Break From Bullish Profitability Narratives
Pacific Biosciences of California (PACB) reported Q4 revenue of US$44.6 million and an EPS loss of US$0.13, with trailing twelve-month revenue at US$160.0 million and an EPS loss of US$1.82. Despite current losses, bulls look to expanding global genomics and clinical use as long-term drivers, while bears highlight persistent unprofitability and insider selling. The company’s stock trades at a P/S of 3.2x, below industry and peer averages, reflecting ongoing market skepticism given its financial performance.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 1Q 2026: Revenue $37.18M, EPS ($0.03) — 10-Q Summary
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) reported its first-quarter 2026 results, showing essentially flat revenue at $37.18M but a significantly narrowed loss with diluted EPS of ($0.03) compared to ($1.44) in the prior year. The company achieved positive gross profit, reduced R&D and SG&A expenses, and completed an asset sale to Illumina, while planning future product launches.
[10-Q] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Quarterly Earnings Report
Pacific Biosciences of California, Inc. (PACB) reported Q1 2026 revenue of $37.2 million, flat year-over-year, with higher consumable sales offsetting declines in instrument and service revenue. The company significantly narrowed its net loss to $8.3 million, down from $426.1 million in Q1 2025, largely due to a $45.8 million gain on an asset sale to Illumina and reduced operating expenses. PACB expects sequential revenue growth in Q2 2026 and further improvements in the second half of the year driven by clinical adoption, SPRQ-Nx consumable growth, and its Basecamp Research program.
Pacific Biosciences Of California (PACB) Q4 Loss Highlights Ongoing Break From Bullish Profitability Narratives
Pacific Biosciences of California (PACB) recently reported its Q4 FY 2025 results, showing a basic EPS loss of US$0.13 on US$44.6 million in revenue, contributing to a TTM basic EPS loss of US$1.82 and TTM net losses of US$546.4 million. Despite revenue growth of 10.9% per year, losses have persisted, with the company expected to remain unprofitable for the next three years. The stock currently trades at a P/S of 3.2x, below industry and peer averages, amid ongoing insider selling and cautions from analysts regarding its path to profitability.
Why PacBio (PACB) Shares Are Getting Obliterated Today
Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) fell 14.2% today after reporting mixed first-quarter 2026 results with a significant revenue miss. Although the adjusted loss per share was narrower than expected, the flat year-on-year revenue of $37.18 million fell short of Wall Street's $40 million expectation, raising concerns about the company's growth trajectory and continued negative margins and cash burn. The stock has been highly volatile, and this news significantly impacted market perception, with the shares down 24.7% year-to-date.
Pacific Biosciences of California, Inc. (PACB) Stock Rises on Q1 2026 Earnings
This article reports that Pacific Biosciences of California, Inc.'s stock (PACB) rose due to its Q1 2026 earnings. The specific details of the earnings and the extent of the stock rise are not provided in this document.
PacBio tumbles after narrowing full-year revenue guidance
PacBio's stock tumbled after the company narrowed its full-year revenue guidance, with analysts citing a slower than expected ramp-up for its Revio system. Despite a beat on Q1 revenue and strong Revio placements, the revised outlook and increased operating expenses led to a negative market reaction.
Long-read sequencing is not the trade-off it used to be: These are the 5 questions that show why
This article argues that long-read sequencing, specifically PacBio's HiFi technology, no longer involves the significant trade-offs in accuracy, cost, or sample input that it once did. The author addresses five common questions about long-read sequencing, highlighting HiFi's ability to deliver highly accurate, comprehensive data including structural variants and methylation, often at a comparable cost to short-read methods. The article emphasizes the efficiency and rich data output of HiFi sequencing for various biological applications.
CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3
CCORF has reiterated its Buy rating for Pacific Biosciences of California (PACB.US) and maintained its target price at $3. This indicates a continued positive outlook from the analyst firm for the company's stock performance.
Pacific Biosciences of California, Inc. Q1 2026 Earnings Call Summary
Pacific Biosciences of California (PacBio) delivered a strong Q1 2026 for consumable revenue, driven by a 100% year-over-year increase in clinical accounts. While instrument revenue faced headwinds from academic funding and geopolitical issues, the company is strategically shifting towards clinical and commercial segments and anticipates significant growth from the late Q2 launch of SPRQ-Nx chemistry. Despite rising compute costs impacting gross margins, PacBio narrowed its full-year revenue guidance to $165 million to $175 million, expecting continued clinical adoption and leveraging a three-platform strategy for diverse customer needs.
Pacific Biosciences of California Q1 Earnings Call Highlights
Pacific Biosciences of California (PACB) reported Q1 2026 revenue of $37.2 million, flat year-over-year, as record consumables revenue was offset by weaker instrument performance due to academic and government funding pressures. The company highlighted significant growth in clinical consumable shipments and progress on strategic priorities like the collaboration with Basecamp Research for AI model development. Despite a lowered revenue outlook for the full year 2026 ($165M-$175M), driven by anticipated continued softness in academic funding, management remains optimistic about the upcoming SPRQ-Nx chemistry launch and new clinical collaborations.
Pacific Biosciences Reports Q1 Revenues Of $37 Mln
Pacific Biosciences of California Inc. reported Q1 2026 net revenues of $37.18 million, stable year-over-year, with a narrowed non-GAAP net loss of $35.9 million. The company forecasts total revenues of $165 million to $175 million for 2026, building on successful Revio and Vega system placements and increased revenue from the EMEA region. Significant business updates include the sale of short-read assets for $48.10 million and collaborations for large-scale genome sequencing projects.
Pacific Biosciences of California (PACB) reports Q1 loss, lags revenue estimates
Pacific Biosciences of California (PACB) reported a Q1 loss that was wider than anticipated, experiencing a significant decline in revenue. The company's revenue of $37.5 million fell short of expectations, indicating a challenging quarter for the genomics sequencing firm.
Pacific Biosciences of California, Inc. (PACB) Stock Rises on Q1 2026 Earnings
Pacific Biosciences of California, Inc. (PACB) reported its Q1 2026 earnings, showing a 2.65% stock price increase since market close despite mixed financial results where revenue missed estimates but EPS beat them. The report details insider trading activity, primarily sales, along with significant institutional investor movements and government contract awards. Analyst ratings include one "Overweight" rating and a median price target of $2.0 from recent analyst reports.
Pacific Biosciences: Q1 Earnings Snapshot
Pacific Biosciences of California Inc. (PACB) reported a first-quarter loss of $8.3 million, translating to 3 cents per share. After adjustments for non-recurring gains, the loss per share was 12 cents. The genetic analysis technology company also announced revenues of $37.2 million for the period.
PacBio Announces First Quarter 2026 Financial Results
PacBio announced its Q1 2026 financial results, showing consumable revenue growth but lower-than-expected instrument revenue due to Vega sales. The company highlighted strategic progress, including the SPRQ-Nx beta program expansion and a collaboration with Basecamp Research for the Trillion Gene Atlas. PacBio anticipates full-year 2026 revenue between $165 million and $175 million.
PacBio (NASDAQ:PACB) Misses Q1 CY2026 Sales Expectations
PacBio (NASDAQ:PACB) reported Q1 CY2026 sales of $37.18 million, flat year-on-year and missing analyst estimates of $40 million. Despite the revenue miss, the company's non-GAAP loss of $0.12 per share was better than the consensus estimate of -$0.13. PacBio highlighted increased clinical adoption of HiFi technology and growth in consumable revenue, while acknowledging lower-than-expected instrument revenue.
PacBio (NASDAQ: PACB) trims Q1 2026 loss, sets $165M–$175M revenue outlook
PacBio reported flat revenue of $37.2 million for Q1 2026 compared to Q1 2025, with stronger consumable sales offsetting weaker instrument sales. The company significantly narrowed its GAAP net loss to $8.3 million from $426.1 million year-over-year, largely due to restructuring actions and a gain from the sale of short-read sequencing assets. PacBio provided a full-year 2026 revenue guidance of $165 million to $175 million, anticipating growth driven by increased clinical adoption of HiFi sequencing and the rollout of its SPRQ-Nx system.
Pacific Biosciences: Q1 Earnings Snapshot
Pacific Biosciences of California Inc. (PACB) reported a first-quarter loss of $8.3 million, translating to 3 cents per share. After adjusting for non-recurring gains, the company's loss was 12 cents per share. The genetic analysis technology maker achieved revenue of $37.2 million for the period.
PacBio (PACB) Q1 Earnings Report Preview: What To Look For
Pacific Biosciences of California (PACB) is set to report its Q1 earnings this Thursday, with analysts expecting a 7.7% year-on-year revenue growth after a decline in the same quarter last year. The company's previous quarter saw it beat both revenue and EPS estimates, leading to increased bullish sentiment among analysts. Investors will be watching key revenue figures, especially given PacBio's history of missing Wall Street estimates and recent positive performance from peers like Illumina and West Pharmaceutical Services.
Pacific Biosciences of California pushes whole genome sequencing to transform newborn care
Pacific Biosciences of California is advocating for the integration of whole genome sequencing (WGS) into newborn care to provide a lasting genomic record and shorten the diagnostic journey for families. The company highlights its advanced WGS technology as a means to move beyond traditional screening methods, enabling earlier and more proactive medical interventions. This initiative aims to improve health outcomes for newborns by offering comprehensive genetic insights from birth.
AI powers deep genomics gains as Pacific Biosciences of California improves sequencing accuracy and reduces costs
Pacific Biosciences of California has significantly lowered the cost of human genome sequencing to $345 per genome, thanks to its SPRQ-Nx platform and AI-driven analysis, including enhancements to DeepConsensus software in collaboration with AlphaEvolve. This advancement also boosts the accuracy of PacBio HiFi reads, making high-fidelity genomic data more accessible. These improvements are expected to accelerate progress in personalized medicine and large-scale genomic research, building on previous initiatives in cancer genomics and structural variant detection.
Pacific Biosciences of California (PACB) Projected to Post Quarterly Earnings on Thursday
Pacific Biosciences of California (PACB) is expected to announce its Q1 2026 earnings on Thursday, May 7th, with analysts projecting a loss of $0.17 per share and revenue of $39.98 million. The stock has been trading down, and analysts have a "Reduce" consensus rating with an average target price of $1.67, with recent price target cuts from firms like Barclays. Insider selling has occurred, and the company faces profitability challenges despite strong liquidity.
Pacific Biosciences of California presents new AAV workflow to reduce partial snapback genomes
Pacific Biosciences of California has introduced a new heat-then-extract workflow for adeno-associated virus (AAV) genome analysis. This innovative method aims to reduce partial snapback genomes and increase the proportion of full-length genomes, offering significant improvements for researchers in gene therapy and genome sequencing. The company will present these findings at the ASGCT2026 conference, continuing its focus on advancing genome analysis technologies.
Improving HiFi sequencing accuracy with Google DeepConsensus and AlphaEvolve
PacBio and Google AI Genomics have collaborated to enhance HiFi sequencing accuracy using DeepConsensus, a transformer-based deep learning model, and Google's AlphaEvolve AI coding agent. These advancements, including an upcoming Revio update with multi-use SMRT Cells and SPRQ-Nx chemistry, are set to reduce the cost per HiFi human genome to approximately $345 while significantly improving read quality and data processing speeds. The integration of AI in genomics is creating a feedback loop where better data leads to better models, and AI systems are now actively optimizing these models, accelerating discovery in various biological fields.
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know
Pacific Biosciences of California (PACB) shares closed down 6.96% at $1.47, underperforming the broader S&P 500. The company is set to report earnings on May 7, 2026, with analysts anticipating an EPS of -$0.17 and revenue of $41 million. Despite the recent dip, the stock has gained 19.7% over the past month, and currently holds a Zacks Rank #3 (Hold).
Sequencing performance advances drive Pacific Biosciences of California to revamp SMRT Cell 101 resource
Pacific Biosciences of California has updated its SMRT Cell Sequencing 101 guide to reflect the latest advancements in its PacBio HiFi sequencing, including the integration of SPRQ-Nx chemistry. This revision provides an up-to-date view of sequencing capabilities in a single run. The company continues to focus on enhancing high-accuracy genomic analysis tools, previously launching the HiFi sequencing and Vega system for oncology and introducing new solutions for whole genome sequencing and cancer variant detection.
Pacific Biosciences of California (PACB) Suffers a Larger Drop Than the General Market: Key Insights
Pacific Biosciences of California (PACB) recently experienced a significant stock drop, underperforming the general market. This article aims to provide investors with key insights into the company's recent performance and underlying factors. Investors might find this information useful for making informed decisions regarding PACB stock.
Pacific Biosciences of California (PACB) laps the stock market: Here's why
The article discusses why Pacific Biosciences of California (PACB) is outperforming the stock market. It likely delves into factors contributing to its strong performance, such as recent developments, financial results, or market sentiment surrounding the company.
Pacific Biosciences of California launches PRISM San Diego, unveils SPRQ-Nx chemistry and Vega system
Pacific Biosciences of California (PacBio) launched its latest SPRQ-Nx chemistry and the Vega system at the PRISM San Diego event. The event featured sessions on cancer and RNA diversity, alongside a Women in Life Science lunch, demonstrating strong community interest in PacBio's technological advancements. PacBio continues to drive innovation in life sciences, building on previous presentations of its HiFi sequencing and Vega system at AACR26 and the introduction of new methods for detecting complex cancer variants.
[ARS] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. SEC Filing
This article announces an ARS SEC filing by PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) on April 23, 2026. The filing is available as a PDF document and is categorized with a low impact and neutral sentiment. Additional information provided includes PACB's stock overview, rankings, and recent news and SEC filings.
PacBio (NASDAQ: PACB) plans 2026 virtual meeting, 16M-share equity plan boost
Pacific Biosciences (NASDAQ: PACB) will hold its 2026 Annual Meeting of Stockholders virtually on June 3, 2026, where key proposals include electing directors, ratifying Ernst & Young LLP as auditor, approving 2025 executive compensation on an advisory basis, and amending the 2020 Equity Incentive Plan to add 16 million shares. The company highlighted its 2025 financial performance, including $160.0 million in revenue and increased sales of its Revio and Vega systems. Discussions with shareholders influenced compensation practices, with continued emphasis on rigorous performance goals and balanced equity awards to attract and retain talent in a competitive market.
Pacific Biosciences of California (PACB) stock declines while market improves: Some information for investors
This article reports that Pacific Biosciences of California (PACB) experienced a stock decline on a trading day where the broader market saw improvements, as indicated by gains in the S&P 500 and Nasdaq. The stock fell 2.59% to $2.26, underperforming both its industry and the major indices. PACB's performance is further detailed with comparisons to its 52-week high, low, and recent analyst ratings.
